Short answer
PRECIGEN, INC. (PGEN) filed its Q2 2026 10-Q quarterly report on Aug 4, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $55M with net income of $20M.
Q2 2026 key financials · XBRL
- Revenue
- $55M
- +136.4% QoQ
- Net income
- $20M
- +175.3% YoY · +353.1% QoQ
- Operating margin
- 41.2%
- EPS (diluted)
- $0.05
- +155.6% YoY · +350.0% QoQ
Source: XBRL data from the PRECIGEN, INC. (PGEN) Q2 2026 10-Q on SEC EDGAR. USD.
PRECIGEN, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $54.978M vs $856K YoY, up $54.122M, driven by Papzimeos product revenue $53.262M
- Operating margin 41.2% vs negative 3,711.2% YoY; net income $20.071M vs $26.642M loss
- Best-performing line: Papzimeos, $53.1M Q2 sales; Exemplar service revenue $1.716M
- R&D expense $7.282M, down 36.6% YoY; SG&A $22.249M, up 37.9% on commercialization
- Gross margins expected to stabilize between high 80 percentages and low 90 percentages after pre-launch inventory sales
Risk Factors
- No material risk-factor changes disclosed; filing refers readers to Annual Report risks
- Insider-trading governance risk: CEO trading arrangement modified June 30, 2026
- Potential market overhang: remaining 130,424 shares eligible for CEO sales
- Securities-law compliance exposure: future Rule 10b5-1 transactions require Section 16 disclosure
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PRECIGEN, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.